A 48-year-old man with a 10-year history of acanthosis nigricans secondary to obesity and insulin resistance is compared with a 65-year-old woman who developed acanthosis nigricans over 3 months alongside unintentional weight loss and abdominal pain. Which finding most reliably distinguishes the metabolic form from the paraneoplastic form in this scenario?

Explanation

## Metabolic vs. Paraneoplastic Acanthosis Nigricans: Clinical Discrimination ### Core Distinction **Key Point:** The most reliable clinical discriminator between benign (metabolic) and malignancy-associated acanthosis nigricans is the **clinical context**: metabolic AN occurs in patients with insulin resistance, obesity, and metabolic syndrome *without constitutional symptoms or unexplained weight loss*, whereas paraneoplastic AN is accompanied by **B symptoms (fever, night sweats), unintentional weight loss, and systemic signs** pointing to an underlying malignancy. ### Clinical Context Comparison | Aspect | Metabolic AN | Paraneoplastic AN | |--------|--------------|------------------| | **Weight trajectory** | Stable or progressive gain | Unintentional loss | | **Constitutional symptoms** | Absent | Present (fever, night sweats) | | **Systemic complaints** | Related to diabetes/metabolic disease | Organ-specific (abdominal pain, dysphagia, cough) | | **Timeline** | Years of gradual onset | Weeks to months, acute | | **Metabolic markers** | Elevated insulin, glucose, lipids | May be normal; focus on malignancy workup | | **Malignancy prevalence** | 0% (by definition) | ~90% have underlying cancer | ### Why Option 2 Is Correct **High-Yield:** The **clinical context** — specifically the absence of constitutional symptoms and stable weight in a patient with documented metabolic syndrome — is the single most reliable feature distinguishing benign from paraneoplastic AN. The 10-year stable history in the obese, insulin-resistant patient confirms metabolic aetiology; the 3-month acute onset with weight loss and abdominal pain in the second patient raises immediate concern for malignancy. **Clinical Pearl:** Any patient presenting with acanthosis nigricans and *unexplained weight loss* or *new systemic symptoms* requires urgent malignancy screening (CT chest/abdomen/pelvis, upper GI endoscopy if indicated). Conversely, a long-standing, stable AN in an obese diabetic patient with no red flags requires no malignancy workup. ### Why Each Distractor Is Wrong 1. **Option 0 (Degree of hyperkeratosis and papillomatosis on histology):** Histological findings are **identical** in metabolic and paraneoplastic AN — both show acanthosis, papillomatosis, and hyperkeratosis. Histology cannot discriminate between the two forms; it only confirms the diagnosis of acanthosis nigricans. This is a common misconception. 2. **Option 1 (Response to topical retinoids and salicylic acid):** Both metabolic and paraneoplastic AN may show partial improvement with topical agents, and neither form reliably responds to these treatments. Response to topical therapy does not distinguish between aetiologies and is not a reliable discriminator. 3. **Option 3 (Presence of hyperpigmentation in palms and soles):** While palmoplantar involvement may be slightly more common in paraneoplastic forms, it is not pathognomonic and can occur in both metabolic and malignancy-associated AN. This finding alone is insufficient to reliably discriminate between the two forms.